How to buy Alpine Immune Sciences stock (ALPN)

Alpine Immune Sciences is a biotechnology business based in the US. Alpine Immune Sciences shares (ALPN) are listed on the NASDAQ and all prices are listed in US Dollars. Alpine Immune Sciences employs 142 staff and has a trailing 12-month revenue of around $56.5 million.

Our top picks for where to buy Alpine Immune Sciences stock

Buy Alpine Immune Sciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Alpine Immune Sciences stock price (NASDAQ: ALPN)

Use our graph to track the performance of ALPN stocks over time.

Alpine Immune Sciences shares at a glance

• Key figures

Information last updated 2024-11-03.

52-week range	$17.32 - $64.97
50-day moving average more info button	$53.15
200-day moving average more info button	$26.84
Wall St. target price	$62.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.64

Is it a good time to buy Alpine Immune Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alpine Immune Sciences financials

Revenue TTM	$56.5 million
Gross profit TTM	$-40,179,000
Return on assets TTM	-10.1%
Return on equity TTM	-14.67%
Profit margin	-65.17%
Book value	$5.08
Market Capitalization more info button	$4.5 billion

TTM: trailing 12 months

Alpine Immune Sciences share dividends

We're not expecting Alpine Immune Sciences to pay a dividend over the next 12 months.

Have Alpine Immune Sciences's shares ever split?

Alpine Immune Sciences's shares were split on a 1:4 basis on 24 July 2017 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alpine Immune Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Alpine Immune Sciences shares which in turn could have impacted Alpine Immune Sciences's share price.

Alpine Immune Sciences share price volatility

Over the last 12 months, Alpine Immune Sciences's shares have ranged in value from as little as $17.32 up to $64.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alpine Immune Sciences's is 0.969. This would suggest that Alpine Immune Sciences's shares are less volatile than average (for this exchange).

Alpine Immune Sciences overview

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc.

Frequently asked questions

null
What percentage of Alpine Immune Sciences is owned by insiders or institutions?
Currently 4.65% of Alpine Immune Sciences shares are held by insiders and 99.469% by institutions. How many people work for Alpine Immune Sciences?
Latest data suggests 142 work at Alpine Immune Sciences. When does the fiscal year end for Alpine Immune Sciences?
Alpine Immune Sciences's fiscal year ends in December. Where is Alpine Immune Sciences based?
Alpine Immune Sciences's address is: 188 East Blaine Street, Seattle, WA, United States, 98102 What is Alpine Immune Sciences's ISIN number?
Alpine Immune Sciences's international securities identification number is: US02083G1004 What is Alpine Immune Sciences's CUSIP number?
Alpine Immune Sciences's Committee on Uniform Securities Identification Procedures number is: 65481J109